Study of dupilumab and cemiplimab before lung cancer surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests two drugs, dupilumab and cemiplimab, given before surgery for early-stage lung cancer. The goal is to see if these immune-boosting medicines can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early-stage non-small cell lung cancer (NSCLC) that is at least 1 cm in size and can be removed with surgery.
- You are willing to have a needle biopsy of the tumor and give blood samples before starting treatment.
- You are at least 18 years old and have a good performance status (ECOG 0 or 1, meaning you can do daily activities without help).
- You do NOT have an autoimmune disorder (like lupus or rheumatoid arthritis) and have NOT used immune-modulating drugs (like dupilumab) in the last 8 weeks.
- You have not had chemotherapy or radiation for another cancer in the last 4 months.
- You are not pregnant or nursing, and you agree to use birth control during and for 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two drugs, cemiplimab and dupilumab, given before surgery for early-stage non-small cell lung cancer. The goal is to see if these drugs can shrink the tumor and improve outcomes.
This trial tests whether giving the drug cemiplimab before surgery can help treat early-stage non-small cell lung cancer. The goal is to see if it shrinks the tumor or improves outcomes when followed by standard surgery.
This trial tests if the drug cemiplimab can prevent non-small cell lung cancer from coming back after surgery. It's for people whose tumors have PD-L1 levels of at least 1% and who are not receiving standard chemotherapy after surgery.
This trial tests giving just three cycles of immunotherapy (cemiplimab) without surgery or radiation, specifically for people with early-stage (stage IA) non-small cell lung cancer who cannot have surgery. It aims to see if this shorter treatment can control the cancer with fewer side effects.
This observational study looks at how well cemiplimab works and how safe it is for adults with advanced non-small cell lung cancer in everyday care in Europe. It mainly follows patients already prescribed cemiplimab, and asks them to complete questionnaires.
This trial tests whether giving two immunotherapy drugs directly into the tumor before surgery can shrink non-small cell lung cancer and improve outcomes. It is for people with early-stage (IIIA) lung cancer who are candidates for surgery.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.